Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2

Small molecules in the treatment of COVID-19

Targeting lung inflammation: novel therapies for the treatment of COPD. - Abstract - Europe PMC

Full article: Future therapeutic treatment of COPD: Struggle between oxidants and cytokines

Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2

Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists

Chemokines and Chemokine Receptors - Creative Diagnostics

Targeting chemokines: Pathogens can, why can't we? - ScienceDirect

Lihu Yang's research works Merck & Co., Whitehouse Station (MSD) and other places

Small molecules in the treatment of COVID-19

Division of Medicinal Chemistry ABSTRACTS - ACS Division of

Structural Analysis of Chemokine Receptor–Ligand Interactions